New stroke drug shows promise in early safety trial

NCT ID NCT00821821

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called Edaravone (MCI-186) in 36 people who had an acute ischemic stroke. The goal was to check the drug's safety and how the body processes it. Participants received either Edaravone or a placebo through an IV over 72 hours. The trial was completed, but it was too small to determine if the drug improves stroke recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Edaravone (MCI-186)

What this could lead to

If successful, this could point toward a treatment to limit brain damage after a stroke.

What could go wrong

This is a small, early-phase trial focused on safety and drug levels, not on proving the drug works. The results may not lead to a proven treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE (AIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Erasmus Medical Center

    Rotterdam, Netherlands

  • Helsinki University Central Hospital

    Helsinki, Finland

  • Newcastle upon Tyne Hospitals NHS Foundation Trust

    Newcastle, United Kingdom